European Archives - Page 359 of 1541 - European Medical Journal

PPM1D Mutations in Patients with Clonal Haematopoiesis and Clonal Cytopenias

TP53 and PPM1D are key regulators of DNA damage response and repair, and somatic mutations in these genes often…

Ranking Treatments for Lenalidomide-Refractory Multiple Myeloma post DRd

Multiple myeloma is the second most common haematological malignancy, with an increasing global incidence…

Review of the European Hematology Association (EHA) 2025 Congress

THE 30ᵗʰ EUROPEAN Hematology Association (EHA) Congress was held in the beautiful city of Milan, Italy from the 12ᵗʰ–15ᵗʰ of June 2025…

Prognostic Assessment in AL Amyloidosis

Systemic light chain (AL) amyloidosis is a rare plasma cell dyscrasia characterised by the extracellular deposition of misfolded Ig light…

Re-evaluating European Haemophilia Standards

TEST In this feature, the authors critically analyse the European standards for Haemophilia Treatment Centres (HTC), examining their…

Hydroxyurea and Gut Function in Sickle Cell Disease Mice

Sickle cell disease (SCD) is a genetic disorder characterised by chronic inflammation, vaso-occlusion, and endothelial…

The Immunotherapy Landscape for Multiple Myeloma

Take a look at our latest haematology infographic, which explores the current immunotherapy treatment landscape for multiple myeloma…

Rituximab in Adults with Autoimmune Haematological Disorders

Rituximab, a monoclonal anti-CD20 antibody, has proven to be an excellent therapeutic agent for haematological diseases. Low-dose…

Long-Term Outcomes After Allo-HSCT in ALL

Patients (pts) with acute lymphoblastic leukaemia (ALL) in difficult first complete remission (CR) or in second CR, and…

Putting Patients First in Haematology

During the Specialized Working Group session, ‘Quality of Life and Symptoms: Promoting Connection Between Patients and Clinicians’, which…